The antitumor effects of BMN673 against ATM-deficient CRC cells were confirmed in vivo by employing a subcutaneous xenograft model in nude mice, wherein BMN673 administration significantly inhibited tumor growth, as evidenced by reduced tumor volumes and weights (Fig. 1d-f). The gene discussed is ATM; the disease is neoplasm.